GHS-R1a comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with amidated C-terminus |
| Molecular weight | 711.85 g/mol | Monoisotopic mass |
| Primary receptor | GHS-R1a | Ghrelin receptor, Gq/11 coupled |
| Peptide class | Synthetic pentapeptide | Contains two non-natural residues |
| Reported selectivity | Lower cortisol and prolactin effect | Observed in animal and early human work |
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
== Side effects == Common side effects of silicone gel sheets include itchiness, rash, maceration of the skin, and malodor. These symptoms are generally well-tolerated and can be minimized by rinsing the area properly daily. Patients who suffer from these side effects should wash the treated area and the silicone gel sheets with mild soap since the dirt or bacteria on the sheets may irritate the scar. In tropical climates with high humidity, excessive moisture underneath the gel may lead to heat rash and uncomfortable sensations in patients.
== Screening == The United States Preventive Services Task Force stated, as of 2013, that there was insufficient evidence to recommend for or against screening for glaucoma. Therefore, there is no national screening program in the US. Screening, however, is recommended starting at age 40 by the American Academy of Ophthalmology. There is no screening program in the UK; however, opportunistic testing is recommended for at-risk groups, including free eye tests.
== Production == Putrescine is produced on an industrial scale by the hydrogenation of succinonitrile. Biotechnological production of putrescine from a renewable feedstock has been investigated. A metabolically engineered strain of Escherichia coli that produces putrescine at high concentrations in glucose mineral salts medium has been described.
Sources: en.wikipedia.org
== External links == Jimenez, Francisco; López, Esmeralda; Bertolini, Marta; Alam, Majid; Chéret, Jérémy; et al. (2021). "Topical odorant application of the specific olfactory receptor OR2AT4 agonist, Sandalore, improves telogen effluvium-associated parameters". Journal of Cosmetic Dermatology. 20 (3): 784–791. doi:10.1111/jocd.13608. ISSN 1473-2130. PMID 32645251. Clinical trial on effect of Sandalore on hair loss.
Kenney, Padraic. 1989: Democratic Revolutions at the Cold War's End: A Brief History with Documents (2009) covers Poland, the Philippines, Chile, South Africa, Ukraine, and China Leffler, Melvyn P. For the Soul of Mankind: The United States, the Soviet Union, and the Cold War (2007) pp 338–450. Mann, James. The Rebellion of Ronald Reagan: A History of the End of the Cold War (2010). popular Matlock, Jack F. Autopsy on an Empire (1995) online by US ambassador to Moscow Matlock, Jack F. Reagan and Gorbachev : how the Cold War ended (2004) online Powaski, Ronald E. The Cold War: The United States and the Soviet Union, 1917–1991 (1998) Romero, Federico. "Cold War historiography at the crossroads." Cold War History 14.4 (2014): 685–703. online Shultz, George P. Turmoil and Triumph: My Years as Secretary of State (1993), a primary source Wilson, James Graham. The Triumph of Improvisation: Gorbachev's Adaptability, Reagan's Engagement, and the End of the Cold War (2014) Wohlforth, William C. "Realism and the End of the Cold War." International Security 19.3 (1994): 91–129. online Zubok, Vladislav M. "Gorbachev and the End of the Cold War: Perspectives on History and Personality," Cold War History (2002) 2:2, 61–100, DOI: 10.1080/713999954 Zubok, Vladislav M. A failed empire: the Soviet Union in the Cold War from Stalin to Gorbachev (2009). online Archived 2020-09-19 at the Wayback Machine
==== Subsidies for Affordable Care Act ("Obamacare") ==== On January 8, 2026, the House voted 230–196 to extend the higher Biden-era subsidies for another three years. Without this extension, it's estimated that monthly premiums will double for many persons who are signed up for the Affordable Care Act. One House Republican said, "I am voting in favor of this discharge and of this legislation to send it to the Senate, so that the Senate will have the opportunity to put forth a reform package that can pass Congress and become law."
Recent studies demonstrated that caspase-1-mediated pyroptosis, a highly inflammatory form of programmed cell death, drives CD4 T-cell depletion and inflammation by HIV. These are the two signature events that propel HIV disease progression to AIDS. Pyroptosis appears to create a pathogenic vicious cycle in which dying CD4 T cells and other immune cells (including macrophages and neutrophils) release inflammatory signals that recruit more cells into the infected lymphoid tissues to die. The feed-forward nature of this inflammatory response produces chronic inflammation and tissue injury. Identifying pyroptosis as the predominant mechanism that causes CD4 T-cell depletion and chronic inflammation, provides novel therapeutic opportunities, namely caspase-1 which controls the pyroptotic pathway. In this regard, pyroptosis of CD4 T cells and secretion of pro-inflammatory cytokines such as IL-1β and IL-18 can be blocked in HIV-infected human lymphoid tissues by addition of the caspase-1 inhibitor VX-765, which has already proven to be safe and well tolerated in phase II human clinical trials. These findings could propel development of an entirely new class of "anti-AIDS" therapies that act by targeting the host rather than the virus. Such agents would almost certainly be used in combination with ART. By promoting "tolerance" of the virus instead of suppressing its replication, VX-765 or related drugs may mimic the evolutionary solutions occurring in multiple monkey hosts (e.g.
Sources: en.wikipedia.org
Certain other achievements of the democratic period having to do with the management of governmental and civic institutions necessary to the functioning of the reunited state and nation were too easily overlooked. Lurking on the sidelines was a disgusted army officer corps unwilling to subject itself to civilian control, but ready to follow the retired Piłsudski, who was highly popular with Poles and just as dissatisfied with the Polish system of government as his former colleagues in the military.
Veratridine acts as a neurotoxin by increasing nerve excitability. It binds to binding site 2 on the voltage-gated sodium channels (the same site bound by batrachotoxin, aconitine, and grayanotoxin), leading to persistent activation. Veratridine inhibits sodium channel inactivation by shifting the activation threshold toward a more negative potential. The resulting influx of Na+ also leads to the increase of intracellular Ca2+ concentrations, causing the overproduction of reactive oxygen species responsible for neuronal damage. Veratridine is readily absorbed through the skin and mucous membranes and through ingestion. The tissues most affected are the heart, nerves, and skeletal muscles: main symptoms of veratridine toxicity include severe nausea, bradycardia, hypotension, difficulty breathing, salivation, and muscle weakness. Treatment involves the administration of activated charcoal, atropine, and benzodiazepines (if the affected individual is seizing). Veratridine's ability to depolarize cells by affecting sodium channels lends it its applicability as a neuropharmacological tool for the study of electrical properties of nerve and muscle fibers. It has also been tested as a treatment for myasthenia gravis, in light of its potential to increase muscle responses to motor neuron stimulation. Furthermore, this compound has recently been reported to increase sperm progressive motility (although it does not produce hyperactivation by itself).
With oral administration, progesterone is rapidly metabolized in the gastrointestinal tract and liver. As many as 30 different metabolites have been found to be formed from progesterone with oral ingestion. Regardless of the route of administration, 5α-reductase is the major enzyme involved in the metabolism of progesterone and is responsible for approximately 60 to 65% of its metabolism. 5β-Reductase is also a major enzyme in the metabolism of progesterone. 5α-Reduction of progesterone occurs predominantly in the intestines (specifically the duodenum), whereas 5β-reduction occurs almost exclusively in the liver. The metabolites of progesterone produced by 5α-reductase and 5β-reductase (after further transformation by 3α-hydroxysteroid dehydrogenase) are allopregnanolone and pregnanolone, respectively. With oral administration of progesterone, they occur in circulation at very high and in fact supraphysiological concentrations that are well in excess of those of progesterone itself (peak concentrations of 30 ng/mL for allopregnanolone and 60 ng/mL for pregnanolone versus 12 ng/mL for progesterone at 4 hours after a single 200-mg oral dose of progesterone). In one study, a single 200-mg oral dose of progesterone resulted in peak levels of 20α-dihydroprogesterone of around 1 ng/mL after 2 hours. The percentage constitutions of progesterone and its metabolites as reflected in serum levels have been determined for a single 100 mg dose of oral or vaginal progesterone.
Sources: en.wikipedia.org
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.
Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.
Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.
Reversed-phase liquid chromatography is standard for purity, and mass spectrometry is standard for identity. Amino acid analysis is used when quantitative composition matters. No single technique answers every question, so laboratories usually combine two or three.